Aquablation uses transrectal ultrasound and computer-guided planning to map the treatment contour. A high-velocity saline jet then removes selected prostate tissue. The cutting step is nonthermal; bleeding is managed afterward with traction, cautery, or other hemostatic technique.
It belongs in the tissue-removing category, not the office-MIST category. Its value proposition is strong relief across a broad anatomic range with more deliberate preservation of tissue near the ejaculatory structures than standard TURP usually provides.
Size, middle lobes, and evidence boundaries
Current FDA labeling does not state a numerical prostate-size limit. Prospective clinical evidence is strongest from 30–150 mL, including large glands and middle lobes. Beyond that range, center experience and individualized planning become even more important.
Randomized data in 30–80 mL glands found symptom and flow improvement comparable to TURP. Large-gland WATER II follow-up shows durable five-year improvement, but it was a prospective single-arm cohort rather than a randomized comparison with HoLEP or simple prostatectomy.
Ejaculation preservation is improved, not guaranteed
Aquablation trials reported substantially less anejaculation than TURP, particularly when the treatment map preserves tissue near the verumontanum and bladder neck. Some men still develop dry, reduced, or altered ejaculation.
The expected rate depends on prostate size, anatomy, number of treatment passes, hemostatic cautery, and the center's planning philosophy. Ask for the surgeon's own outcome definition rather than a generic marketing percentage.
Bleeding is the central perioperative capability
The saline jet removes tissue quickly but does not coagulate while it cuts. Early large-gland studies had meaningful bleeding and transfusion events. Hemostasis protocols have evolved, and experienced programs may use targeted bladder-neck cautery and standardized postoperative monitoring.
A strong program should be able to describe transfusion, return-to-operating-room, clot-retention, catheter, and length-of-stay outcomes by gland size. It should also have a clear anticoagulation plan; current labeling lists inability to safely stop antiplatelet or anticoagulant agents perioperatively as a contraindication.
Recovery and durability
Most patients should expect a catheter and at least a short period of blood, urgency, burning, fatigue, and activity restriction. The recovery is usually shorter than abdominal simple prostatectomy but more substantial than PUL or an uncomplicated office procedure.
Five-year trial follow-up is reassuring, but HoLEP has a longer history and more mature size-independent durability evidence. The decision between Aquablation and enucleation often turns on ejaculation priorities, local surgeon capability, bleeding considerations, and how much uncertainty the patient accepts.
Capability questions for the treating program
- How many procedures has the surgeon and operating team completed?
- What are your transfusion, clot-retention, return-to-OR, and readmission rates for glands my size?
- How will the map address my middle lobe, bladder neck, and ejaculatory structures?
- What catheter duration and hospital stay should I plan for?
- Why is Aquablation preferable to HoLEP, TURP, or simple prostatectomy in my anatomy?
Bottom line
Aquablation can combine strong obstruction relief with a better chance of preserving antegrade ejaculation than TURP, but its success depends on mapping and hemostasis capability—not merely owning the platform.
Sources and evidence
Open the original guideline, regulatory record, or study. Evidence was last checked August 14, 2026.
-
AUA Guideline (2026) Part III: Procedural/Surgical Management The Journal of Urology · professional guideline · 2026
-
Disease Management — Management of Non-neurogenic Male LUTS European Association of Urology · professional guideline · 2026
-
AQUABEAM Robotic System — 510(k) K231024 U.S. Food and Drug Administration · regulatory record · 2023
-
WATER versus WATER II 5-year update: Aquablation in 30–80 and 80–150 mL prostates BJUI Compass · prospective trial follow-up · 2024